Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, Amarendra; Schmidt, Stephen D.; Talana, Chloe Adrienna; Flach, Britta; Luke, Catherine J.; Makowski, Mat; Roberts, Paul C.; Roederer, Mario

doi:10.1126/science.abj4176

Cited by 503 publications

(430 citation statements)

References 33 publications

Supporting

Mentioning

385

Contrasting

Unclassified

Order By: Relevance

“…Currently, all the licensed vaccines have been designed to elicit immune responses to the spike protein for providing protection, therefore, it is reasonable for the assumption that the patterns of neutralizing antibody responses post-vaccination will follow the patterns seen in post-infection follow-up 67,68 . Some recent studies suggested both the binding and neutralizing antibody responses possessed similar rate of decline between vaccination of mRNA vaccine or infection during the first 7 months after vaccination 69,70 , and our study provide further hints for the durability assessment of vaccine induced antibody response. Furthermore, individuals previously diagnosed with COVID-19 could develop potent humoral immunity rapidly after a single dose of mRNA vaccine [71][72][73] .…”

Section: Discussionsupporting

confidence: 69%

Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up

Yang

Peng

et al. 2021

Preprint

View full text Add to dashboard Cite

Elucidation the kinetics of neutralizing antibody response in the coronavirus disease 2019 (COVID-19) convalescents is crucial for the future control of the COVID-19 pandemic and vaccination strategies. Here we tested 411 sequential plasma samples collected up to 480 days post symptoms onset (d.a.o) from 214 convalescents of COVID-19 across clinical spectrum without re-exposure history after recovery and vaccination of SARS-CoV-2, using authentic SARS-CoV-2 microneutralization (MN) assays. COVID-19 convalescents free of re-exposure and vaccination could maintain relatively stable anti-RBD IgG and MN titers during 400~480 d.a.o after the peak at around 120 d.a.o and the subsequent decrease. Undetectable neutralizing activity started to occur in mild and asymptomatic infections during 330 to 480 d.a.o with an overall rate of 14.29% and up to 50% for the asymptomatic infections. Significant decline in MN titers was found in 91.67% COVID-19 convalescents with ≥ 50% decrease in MN titers when comparing the available peak and current MN titers (≥ 300 d.a.o). Antibody-dependent immunity could also provide protection against most of circulating variants after one year, while significantly decreased neutralizing activities against the Beta, Delta and Lambda variants were found in most of individuals. In summary, our results indicated that neutralizing antibody responses could last at least 480 days in most COVID-19 convalescents despite of the obvious decline of neutralizing activity, while the up to 50% undetectable neutralizing activity in the asymptomatic infections is of great concern.

show abstract

Section: Discussionsupporting

confidence: 69%

Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up

Yang

Peng

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…1b). Of note, we performed this assay in all 46 volunteers in Vero-E6 cells to compare with the data we reported recently 6 and all the previous studies where we used this assay 5,[7][8][9] . The durability of neutralizing titers against the homologous strain was comparable to that of the responses in mRNA1273 vaccinees 5,10 .…”

mentioning

confidence: 63%

Durability of immune responses to the BNT162b2 mRNA vaccine

Suthar

Arunachalam

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The development of the highly efficacious mRNA vaccines in less than a year since the emergence of SARS-CoV-2 represents a landmark in vaccinology. However, reports of waning vaccine efficacy, coupled with the emergence of variants of concern that are resistant to antibody neutralization, have raised concerns about the potential lack of durability of immunity to vaccination. We recently reported findings from a comprehensive analysis of innate and adaptive immune responses in 56 healthy volunteers who received two doses of the BNT162b2 vaccination. Here, we analyzed antibody responses to the homologous Wu strain as well as several variants of concern, including the emerging Mu (B.1.621) variant, and T cell responses in a subset of these volunteers at six months (day 210 post-primary vaccination) after the second dose. Our data demonstrate a substantial waning of antibody responses and T cell immunity to SARS-CoV-2 and its variants, at 6 months following the second immunization with the BNT162b2 vaccine. Notably, a significant proportion of vaccinees have neutralizing titers below the detection limit, and suggest a 3rd booster immunization might be warranted to enhance the antibody titers and T cell responses.

show abstract

“…1 However, the emergence of SARS-CoV-2 variants of concern (VOCs) raises questions about the specificity and potential cross-protection mediated by these antibodies. While antibody responses have been extensively studied for vaccinee sera, 2 human milk antibodies – a major contributor to passive immunity for infants – have not been analyzed.…”

Section: Objectivementioning

confidence: 99%

Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern

Low

et al. 2021

Preprint

View full text Add to dashboard Cite

We detected the presence of SARS-CoV-2 specific IgA against all major VOCs in milk out to 6 weeks after D2 of BNT162b2. These likely confer some protection to the breastfed infants, who are ineligible for vaccination and are at risk of severe COVID-19. However, we detected significantly reduced milk IgA binding to VOCs, including the globally dominant Delta variant, suggesting reduced protection for breastfeeding infants. Additionally, these antibodies were significantly reduced by as early as 4-6 weeks after D2.

show abstract

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Cited by 503 publications

References 33 publications

Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up

Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up

Durability of immune responses to the BNT162b2 mRNA vaccine

Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern

Contact Info

Product

Resources

About